KV Pharmaceutical Co. v. Medecor Pharma, L.L.C.

354 F. Supp. 2d 682, 2003 U.S. Dist. LEXIS 26261, 2003 WL 23997723
CourtDistrict Court, E.D. Louisiana
DecidedDecember 2, 2003
DocketCIV.A. 03-3054
StatusPublished
Cited by3 cases

This text of 354 F. Supp. 2d 682 (KV Pharmaceutical Co. v. Medecor Pharma, L.L.C.) is published on Counsel Stack Legal Research, covering District Court, E.D. Louisiana primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
KV Pharmaceutical Co. v. Medecor Pharma, L.L.C., 354 F. Supp. 2d 682, 2003 U.S. Dist. LEXIS 26261, 2003 WL 23997723 (E.D. La. 2003).

Opinion

ORDER AND REASONS

LEMMON, District Judge.

IT IS HEREBY ORDERED that the motion for a preliminary injunction of KV Pharmaceutical Company, Ther-RX Corporation and Drug Tech Corporation is DENIED. (Document # 1.)

I. BACKGROUND

KV Pharmaceutical Company (KV) and its wholly-owned subsidiaries, Ther-RX Corporation (Ther-RX) and Drug Tech Corporation (Drug Tech), filed a “Complaint for Temporary Restraining Order, Injunction and Damages” against Medecor *684 Pharma, L.L.C. (Medecor) alleging breach of contract and trade dress infringement.

Drug Tech is the owner of the trademark “PrimaCare” and KV and Ther-RX are licensees to that intellectual property. The plaintiffs market a line of prescription-vitamin products across the United States under the “Precare” trademark. This case involves the prenatal vitamins in the “PreCare Family” line of vitamins, which are packaged in a yellow, blue, and pink box bearing a photo of a woman and a baby.

Medecor markets and sells a prescription prenatal vitamin known as “TriCare.” The plaintiffs allege that TriCare’s packaging “mimics” KV’s packaging in size, shape, color, terminology, and overall appearance and that the choice of packaging is a deliberate attempt to cause confusion and to appropriate the goodwill of KV’s PreCare products. 1 KV views Medecor’s product as inferior because it does not have the proprietary formulation of the KV product and believes that Medecor’s product would “dirty” its product and cause KV to lose market share to other competitors.

In February 2003, KV formally notified Medecor to cease and desist its infringement of KV’s trademark and trade dress. The parties reached an agreement on July 10, 2003, in which Medecor admitted violating KV’s trade dress and agreed to modify its labeling and packaging. KV paid Medecor $14,000 to compensate it for costs of revising its packaging. Under the agreement, KV is entitled to injunctive relief, attorney’s fees, costs, and the return of the $14,000 if Medecor violates the terms and conditions of the agreement.

The court denied the plaintiffs’ motion for a temporary restraining order and held a hearing on the motion for a preliminary injunction on November 6, 2003.

II. DISCUSSION

A. Standard for preliminary injunction

“[FJederal courts are required to apply the federal rules of civil procedure to the exclusion of any contrary state procedure as long as the rule is both constitutional and within the scope of the rules’ enabling act.” Ferrero v. Assoc. Materials Inc., 923 F.2d 1441, 1448 (11th Cir.1991) (citing Hanna v. Plumer, 380 U.S. 460, 85 S.Ct. 1136, 1143-44, 14 L.Ed.2d 8 (1965)). Rule 65 of the Federal Rules of Civil Procedure meets the Hanna criteria and applies to determine whether to issue a preliminary injunction. Id.

“A preliminary injunction is an extraordinary remedy.” Lakedreams v. Taylor, 932 F.2d 1103, 1107 (5th Cir.1991). Federal law allows a preliminary injunction when the moving party establishes four factors:

(1) a substantial likelihood of success on the merits,
(2) a substantial threat that failure to grant the injunction will result in irreparable injury,
(3) the threatened injury outweighs any damage that the injunction may cause the opposing party, and
(4) the injunction will not disserve the public interest.

Id. The party seeking injunction must clearly carry the burden of persuasion on all four requirements. See Karaha Bodas Co., L.L.C. v. Perusahaan Pertambangan Minyak Dan Gas Bumi Negara, 335 F.3d 357, 363 (5th Cir.2003). The grant of a *685 preliminary injunction is treated as the exception rather than the rule. Id. at 364.

B. Breach of contract

The plaintiffs argue that the court may issue a preliminary injunction without a showing of irreparable harm because the clear language of the agreement obligates the defendant to cease distributing its infringing product and entitles them to a preliminary injunction.

Under Louisiana law, proof of irreparable injury is not required to obtain a preliminary injunction when there is proof of an obligor’s failure to perform. La. Civ.Code art.1987; La.Rev.Stat. 23:921G; Louisiana Gaming Corp. v. Jerry’s Package Store, Inc., 629 So.2d 479, 482 (La.Gt.App.1993) (“Irreparable injury is not an essential condition for the grant of an injunction restraining the- breach of an obligation not to do.”). However, Rule 65 is a procedural rule and applies to determine whether preliminary injunctive relief is appropriate in a diversity case. See Ferrero, 923 F.2d at 1448. Because the plaintiffs are proceeding under Rule 65, there is no authority to relieve them of the requirement to establish irreparable harm to obtain a preliminary injunction.

KV did not present any data for sales and distribution of PreCare in Louisiana or Mississippi to establish irreparable harm. Nor did KV present any data to support the allegations that the distribution of TriCare would “dirty” KV’s line; cause confusion among physicians, patients, and other health care providers; and cause general confusion that would erode KV’s good will. Tr. p. 52.

Brad Sanders, a principal of Medecor, testified at the hearing concerning the manner of marketing and.- distributing TriCare. A sales representatives visits the doctor to talk about using the product, leaves packaged samples with the doctor’s approval, and provides a pre-printed prescription -pad for the doctor’s convenience. The doctor decides which prenatal vitamin is appropriate for each patient and writes a prescription to be filled at a pharmacy. The doctor may give a packaged sample to the patient; however, the packaged product is not available in pharmacies and is distributed in a bottle as a .prescription drug.

There is no showing that any of the doctors who choose among the packaged products did not know the difference between the prenatal vitamins and the source of their distribution. Moreover, in view of the limited distribution of TriCare to the doctors, the calculation of a dollar value, if irreparable harm is ultimately shown, would not be extremely difficult or speculative.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
354 F. Supp. 2d 682, 2003 U.S. Dist. LEXIS 26261, 2003 WL 23997723, Counsel Stack Legal Research, https://law.counselstack.com/opinion/kv-pharmaceutical-co-v-medecor-pharma-llc-laed-2003.